The UK and US have finalized a landmark bilateral deal that will preserve zero tariffs on British medicine exports being sold in the US market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to raise funding on drugs through the NHS. This commitment guarantees that duties on these crucial goods will remain at zero for a timeframe of the next three years.
This deal follows earlier statements to dramatically increase tariffs on branded drug products, with increases mentioned as high as double the cost.
"This agreement between the UK strengthens the worldwide climate for new treatments and brings long-overdue equity to American-British pharmaceutical trade," a statement said.
Commercial Significance
Medicines constitute one of the the United Kingdom's largest exports to the America, which is clearly the largest market for major UK drugmakers.
Trade data indicate that in the year to the end of last September, the UK exported drugs worth £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that period.
"This guarantee protects employment, increases capital expenditure and sets the stage for the UK to emerge as a international leader for life sciences," a government official commented.
Detailed NHS Changes
The agreement entails several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments topped 20%.
Recent Tensions
The pact comes amid a protracted tension between the sector and the UK government over medicine costs and approval rates.
This friction were intensified by arguments that American consumers were charged a premium for the identical medicines than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been directed toward US facilities.
The Science Minister stated that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a percentage of its resources over the last ten years.
